查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584115

Alpha-1 抗胰蛋白酶缺乏症治疗市场，按治疗类型、给药途径、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Alpha-1 Antitrypsin Deficiency Disease Treatment Market, By Treatment Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年Alpha-1抗胰蛋白酶缺乏症治疗市场规模为26.3043亿美元，2024年至2032年复合年增长率为10.10%。

Alpha-1抗胰蛋白酶缺乏症治疗市场-市场动态

人们对遗传性疾病的认识不断提高，推动了 Alpha-1 抗胰蛋白酶缺乏症治疗市场的成长

人们对遗传性疾病的认识不断提高，推动了 Alpha-1 抗胰蛋白酶 (AAT) 缺乏症治疗市场的成长，并且越来越重视早期诊断和有效管理。 AAT 缺乏症是一种影响肺部和肝臟健康的遗传性疾病，促使许多卫生组织和政府扩大筛检计画并向公众宣传其风险。例如，世界卫生组织（WHO）强调了基因检测在检测遗传性疾病的重要性。製药公司也正在加速研发力度，以创造创新疗法。这种意识的激增导致全球 AAT 缺乏症患者对针对性治疗的需求更大，并改善了医疗保健的可近性。

Alpha-1 抗胰蛋白酶缺乏症治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 10.10% 左右的复合年增长率成长

根据治疗类型细分，预计增强疗法将在 2023 年显示最大的市场份额

依给药途径细分，2023年静脉注射为主导类型

按地区划分，北美是 2023 年的主要收入来源

Alpha-1 抗胰蛋白酶缺乏症治疗市场-細項分析：

全球 Alpha-1 抗胰蛋白酶缺乏症治疗市场根据治疗类型、给药途径、最终用户和地区进行细分。

根据治疗类型，市场分为四类：增强疗法、支气管扩张剂疗法、氧气疗法和类固醇疗法。强化疗法因其在补充 AAT 水平方面的直接作用而具有最高优先级。支气管扩张剂疗法用于症状管理，而氧气疗法和类固醇疗法用于严重病例。

根据给药途径，市场分为三类：静脉注射、口服和吸入。静脉途径因其在提供增强治疗方面的有效性而具有最高优先顺序。口服给药是为了方便使用，吸入给药在特定情况下用于缓解症状。

Alpha-1 抗胰蛋白酶缺乏症治疗市场 - 地理洞察

Alpha-1 抗胰蛋白酶 (AAT) 缺乏症治疗市场表现出显着的地域差异，其中北美由于其先进的医疗基础设施和对遗传性疾病认识的高度重视而引领市场。尤其是美国，在 Alpha-1 基金会等组织的支持下，采取了增加基因检测和新生儿筛检计画等措施。欧洲紧随其后，德国和英国等国家大力投资研发以解决 AAT 缺陷。例如，欧洲呼吸学会一直在积极推动宣传活动，以改善早期检测和治疗方案。在亚太地区，医疗保健支出的增加和对遗传性疾病的认识不断提高正在推动市场成长。日本和中国正在扩大其医疗保健系统，包括对 AAT 缺乏症等遗传性疾病进行更全面的筛检。拉丁美洲、中东和非洲正在逐渐受到关注，旨在改善医疗保健和诊断服务的机会的倡议，儘管这些地区仍然面临意识和基础设施方面的挑战。

Alpha-1抗胰蛋白酶缺乏症治疗市场-竞争格局：

Grifols 和武田製药 (Takeda Pharmaceuticals) 等公司是该地区的知名企业。 2023 年，Grifols 扩建了位于北卡罗来纳州的 Prolastin-C Liquid（AAT 增强疗法）製造工厂，以满足不断增长的需求。同时，武田积极参与旨在增强 AAT 治疗解决方案的研究合作。 2024 年，市场主要参与者 CSL Behring 宣布与欧洲肺臟基金会建立合作关係，以提高人们对 AAT 缺乏症的认识。此次合作旨在支持早期诊断和治疗，特别是在疾病识别率较低的地区。亚太地区虽然在成长，但仍处于早期阶段，当地医疗机构和全球公司之间形成了重要的合作伙伴关係，以改善 AAT 疗法的可及性。这些发展凸显了策略性倡议对于推动全球 AAT 治疗市场竞争优势的重要性。

最新进展：

2024 年 1 月，赛诺菲宣布收购 Inhibrx, Inc.，其中包括治疗 Alpha-1 抗胰蛋白酶缺乏症 (AATD) 的候选药物 INBRX-101。此次收购是赛诺菲增强其罕见疾病和免疫学产品组合策略的一部分。

2023 年 4 月，Arrowhead Pharmaceuticals 宣布在一项针对 Alpha-1 抗胰蛋白酶缺乏性肝病 (AATD-LD) 的 3 期临床研究中，首例患者使用其研究疗法 Fazirsiran 进行治疗。这一里程碑触发武田向 Arrowhead 支付 4000 万美元。

目录

第 1 章：Alpha-1 抗胰蛋白酶缺乏症治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • Alpha-1 抗胰蛋白酶缺乏症治疗市场片段（依治疗类型）
    • Alpha-1 抗胰蛋白酶缺乏症治疗市场片段（依给药途径）
    • 最终使用者的 Alpha-1 抗胰蛋白酶缺乏症治疗市场片段
    • Alpha-1 抗胰蛋白酶缺乏症治疗市场片段（依国家/地区）
    • Alpha-1 抗胰蛋白酶缺乏症治疗市场片段（按地区）
  • 竞争洞察

第 3 章：Alpha-1 抗胰蛋白酶缺乏症治疗主要市场趋势

  • Alpha-1 抗胰蛋白酶缺乏症治疗市场驱动因素
    • 市场驱动因素的影响分析
  • Alpha-1抗胰蛋白酶缺乏症治疗市场限制
    • 市场限制影响分析
  • Alpha-1 抗胰蛋白酶缺乏症治疗市场机会
  • Alpha-1抗胰蛋白酶缺乏症治疗市场未来趋势

第 4 章：Alpha-1 抗胰蛋白酶缺乏症治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：Alpha-1 抗胰蛋白酶缺乏症治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：Alpha-1 抗胰蛋白酶缺乏症治疗市场模式

  • Alpha-1 抗胰蛋白酶缺乏症治疗市占率分析，2023 年
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：Alpha-1 抗胰蛋白酶缺乏症治疗市场 - 依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 增强疗法
    • 支气管扩张剂治疗
    • 氧气治疗
    • 类固醇治疗

第 8 章：Alpha-1 抗胰蛋白酶缺乏症治疗市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 静脉
    • 口服
    • 吸入

第 9 章：Alpha-1 抗胰蛋白酶缺乏症治疗市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 专科诊所
    • 家庭护理设置

第 10 章：Alpha-1 抗胰蛋白酶缺乏症治疗市场 - 依地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • Alpha-1 抗胰蛋白酶缺乏症治疗北美主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按治疗类型）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • Alpha-1 抗胰蛋白酶缺乏症治疗欧洲主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按治疗类型）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • Alpha-1抗胰蛋白酶缺乏症治疗药物亚太地区主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按治疗类型）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • Alpha-1 抗胰蛋白酶缺乏症治疗药物拉丁美洲主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按治疗类型）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • Alpha-1 抗胰蛋白酶缺乏症治疗药物中东和非洲主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按治疗类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - Alpha-1 抗胰蛋白酶缺乏症治疗产业

  • 竞争仪表板
  • 公司简介
    • Adverum Biotechnologies, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Baxter International Inc.
    • Biogen Inc.
    • CSL Behring LLC
    • GlaxoSmithKline plc
    • Grifols SA
    • Kamada Ltd.
    • LFB Biopharmaceuticals
    • Pfizer Inc.
    • Prometic Life Sciences Inc.
    • Shire plc
    • Takeda Pharmaceutical Company Limited
    • Vertex Pharmaceuticals Incorporated
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4098

REPORT HIGHLIGHT

Alpha-1 Antitrypsin Deficiency Disease Treatment Market size was valued at USD 2,630.43 Million in 2023, expanding at a CAGR of 10.10% from 2024 to 2032.

The Alpha-1 Antitrypsin Deficiency (AATD) Disease Treatment Market is focused on addressing the needs of individuals with AATD, a genetic disorder that leads to the accumulation of abnormal alpha-1 antitrypsin protein in the liver, resulting in lung and liver disease. Treatments primarily include augmentation therapy, aimed at replacing the deficient protein, as well as liver and lung transplants in severe cases. Increasing awareness about genetic disorders and advancements in gene therapy are boosting research efforts in the market. Despite growing demand, limited treatment availability and high costs remain major restraints. Ongoing research into innovative therapies, such as CRISPR-based solutions, presents opportunities for expanding treatment options. According to the World Health Organization, about 1 in 2,500 individuals globally are affected by AATD, further emphasizing the need for improved and accessible treatments.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Market Dynamics

Rising Awareness of Genetic Disorders Fuels Growth in the Alpha-1 Antitrypsin Deficiency Disease Treatment Market

The rising awareness of genetic disorders is driving growth in the Alpha-1 Antitrypsin (AAT) Deficiency Disease Treatment Market, with increasing emphasis on early diagnosis and effective management. AAT deficiency, a genetic condition affecting lung and liver health, has prompted numerous health organizations and governments to expand screening programs and educate the public about its risks. For instance, the World Health Organization (WHO) has highlighted the importance of genetic testing in detecting hereditary conditions. Pharmaceutical companies are also accelerating research and development efforts to create innovative therapies. This surge in awareness is leading to greater demand for targeted treatments and improved healthcare access for AAT deficiency patients worldwide.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.10% over the forecast period (2024-2032)

Based on Treatment Type segmentation, Augmentation Therapy was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Intravenous was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Segmentation Analysis:

The Global Alpha-1 Antitrypsin Deficiency Disease Treatment Market is segmented on the basis of Treatment Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Treatment Type: Augmentation Therapy, Bronchodilator Therapy, Oxygen Therapy, and Steroid Therapy. Augmentation Therapy holds the highest priority due to its direct role in replenishing AAT levels. Bronchodilator Therapy is used for symptom management, while Oxygen Therapy and Steroid Therapy are used for severe cases.

The market is divided into three categories based on the Route of Administration: Intravenous, Oral, and Inhalation. The Intravenous route holds the highest priority due to its effectiveness in delivering augmentation therapy. Oral administration follows for ease of use, with Inhalation being utilized for symptom relief in specific cases.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Geographical Insights

The Alpha-1 Antitrypsin (AAT) Deficiency Disease Treatment Market shows significant geographical variation, with North America leading the market due to its advanced healthcare infrastructure and strong emphasis on genetic disorder awareness. The U.S., in particular, has seen initiatives such as increased genetic testing and newborn screening programs, supported by organizations like the Alpha-1 Foundation. Europe follows closely, with countries like Germany and the UK investing heavily in research and development to address AAT deficiency. For instance, the European Respiratory Society has been actively promoting awareness campaigns to improve early detection and treatment options. In the Asia-Pacific region, increasing healthcare expenditure and growing awareness about genetic disorders are driving market growth. Japan and China are expanding their healthcare systems to include more comprehensive screening for hereditary diseases like AAT deficiency. Latin America and the Middle East & Africa are gradually gaining traction, with initiatives aimed at improving access to healthcare and diagnostic services, although these regions still face challenges in terms of awareness and infrastructure.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Competitive Landscape:

Companies like Grifols and Takeda Pharmaceuticals are prominent players in this region. In 2023, Grifols expanded its Prolastin-C Liquid (AAT augmentation therapy) manufacturing facility in North Carolina to meet growing demand. Meanwhile, Takeda is actively involved in research collaborations aimed at enhancing AAT therapy solutions. In 2024, CSL Behring, a key player in the market, announced a partnership with the European Lung Foundation to raise awareness about AAT deficiency. This collaboration aims to support earlier diagnosis and treatment, particularly in regions with lower disorder recognition. Asia-Pacific, though growing, remains in its early stages, with key partnerships forming between local healthcare institutions and global firms to improve access to AAT therapies. These developments underline the importance of strategic initiatives in driving competitive advantage in the AAT treatment market globally.

Recent Developments:

In January 2024, Sanofi announced its acquisition of Inhibrx, Inc., which includes the promising treatment candidate INBRX-101 for Alpha-1 Antitrypsin Deficiency (AATD). This acquisition is part of Sanofi's strategy to enhance its rare diseases and immunology portfolio.

In April 2023, Arrowhead Pharmaceuticals announced the first patient's treatment in a Phase 3 clinical study for Alpha-1 Antitrypsin Deficiency Liver Disease (AATD-LD) using their investigational therapy, Fazirsiran. This milestone triggers a $40 million payment from Takeda to Arrowhead.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Adverum Biotechnologies, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Biogen Inc.
  • CSL Behring LLC
  • GlaxoSmithKline plc
  • Grifols S.A.
  • Kamada Ltd.
  • LFB Biopharmaceuticals
  • Pfizer Inc.
  • Prometic Life Sciences Inc.
  • Shire plc
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Others

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Augmentation Therapy
  • Bronchodilator Therapy
  • Oxygen Therapy
  • Steroid Therapy

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Oral
  • Inhalation

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Homecare Settings

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Treatment Type
    • 2.1.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Route of Administration
    • 2.1.3. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by End-User
    • 2.1.4. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Country
    • 2.1.5. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Market Trends

  • 3.1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Opportunities
  • 3.4. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Future Trends

4. Alpha-1 Antitrypsin Deficiency Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Alpha-1 Antitrypsin Deficiency Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Landscape

  • 6.1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Alpha-1 Antitrypsin Deficiency Disease Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 7.1.2. Augmentation Therapy
    • 7.1.3. Bronchodilator Therapy
    • 7.1.4. Oxygen Therapy
    • 7.1.5. Steroid Therapy

8. Alpha-1 Antitrypsin Deficiency Disease Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Intravenous
    • 8.1.3. Oral
    • 8.1.4. Inhalation

9. Alpha-1 Antitrypsin Deficiency Disease Treatment Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Specialty Clinics
    • 9.1.4. Homecare Settings

10. Alpha-1 Antitrypsin Deficiency Disease Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Alpha-1 Antitrypsin Deficiency Disease Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Adverum Biotechnologies, Inc.
    • 11.2.2. Arrowhead Pharmaceuticals, Inc.
    • 11.2.3. AstraZeneca PLC
    • 11.2.4. Baxter International Inc.
    • 11.2.5. Biogen Inc.
    • 11.2.6. CSL Behring LLC
    • 11.2.7. GlaxoSmithKline plc
    • 11.2.8. Grifols S.A.
    • 11.2.9. Kamada Ltd.
    • 11.2.10. LFB Biopharmaceuticals
    • 11.2.11. Pfizer Inc.
    • 11.2.12. Prometic Life Sciences Inc.
    • 11.2.13. Shire plc
    • 11.2.14. Takeda Pharmaceutical Company Limited
    • 11.2.15. Vertex Pharmaceuticals Incorporated
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us